{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:00:00Z","timestamp":1793973600107,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center, Korea","doi-asserted-by":"crossref","award":["1810031"],"award-info":[{"award-number":["1810031"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center, Korea","doi-asserted-by":"crossref","award":["1510520"],"award-info":[{"award-number":["1510520"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jhep.2018.11.029","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T05:19:30Z","timestamp":1544073570000},"page":"684-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":181,"title":["Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-0494","authenticated-orcid":false,"given":"Joong-Won","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Woon","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwi Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Chu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Young","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Youn","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oh Sang","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Eun","family":"Yeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeseok","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.11.029_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015","volume":"3","author":"Global Burden of Disease Liver Cancer C","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2018.11.029_b0010","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.11.029_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2017.0112","article-title":"Epidemiology of liver cancer in South Korea","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2018.11.029_b0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.11.029_b0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.11.029_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2018.11.029_b0035","first-page":"145","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.11.029_b0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3348\/kjr.2015.16.3.465","article-title":"2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma","volume":"16","author":"Korean Liver Cancer Study G, National Cancer Center K","year":"2015","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.jhep.2018.11.029_b0045","series-title":"NCCN clinical practice guideline in oncology: adult cancer pain","author":"Network NCC","year":"2013"},{"key":"10.1016\/j.jhep.2018.11.029_b0050","article-title":"Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)","volume":"34","author":"Abou-Alfa","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.11.029_b0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"Zhu","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.11.029_b0060","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/S0168-8278(16)00173-2","article-title":"Prospective randomized cntrolled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin\/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma","volume":"64","author":"Kudo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.11.029_b0065","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.21873\/anticanres.11211","article-title":"Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a Western randomized controlled trial","volume":"36","author":"Giorgio","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhep.2018.11.029_b0070","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2018.11.029_b0075","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jhep.2012.01.006","article-title":"Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma","volume":"56","author":"Park","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.11.029_b0080","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijrobp.2014.01.017","article-title":"Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma","volume":"88","author":"Chen","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jhep.2018.11.029_b0085","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2018.11.029_b0090","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1349-7006.2008.00909.x","article-title":"Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients","volume":"99","author":"Shim","year":"2008","journal-title":"Cancer Sci"},{"issue":"Suppl 4","key":"10.1016\/j.jhep.2018.11.029_b0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1634\/theoncologist.2010-S4-42","article-title":"Treatment of intermediate\/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?","volume":"15","author":"Lencioni","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2018.11.029_b0100","first-page":"391","article-title":"National Cancer Center Korea: Special Contribution: practice guidelines for management of hepatocellular carcinoma 2009","volume":"15","author":"Korean Liver Cancer Study Group","year":"2009","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2018.11.029_b0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1386-6346(02)00144-4","article-title":"Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis","volume":"24","author":"Ueno","year":"2002","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2018.11.029_b0110","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.11.029_b0115","article-title":"Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2018.11.029_b0120","doi-asserted-by":"crossref","first-page":"29416","DOI":"10.18632\/oncotarget.15075","article-title":"Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2018.11.029_b0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrgastro.2014.10","article-title":"HCC therapies\u2014lessons learned","volume":"11","author":"W\u00f6rns","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.11.029_b0130","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","article-title":"Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design","volume":"20","author":"Llovet","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2018.11.029_b0135","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2018.11.029_b0140","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1200\/JCO.2017.73.8245","article-title":"Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study","volume":"35","author":"Reiss","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.11.029_b0145","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00280-011-1616-x","article-title":"Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function","volume":"68","author":"Kim","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhep.2018.11.029_b0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00432-008-0496-x","article-title":"Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area","volume":"135","author":"Shim","year":"2009","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818325807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818325807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T02:06:42Z","timestamp":1720836402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818325807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0168827818325807"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.11.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}